I think the point they are trying to make is just HOW CONFIDENT THEY ARE ABOUT WINNING but because they are in arbitration they are not allowed to say anything specific. That is why the gave the first 20c to existing PTD shareholders (assuming they win). J&J are 2 from 43 patent fights - not a good ratio. Abbott already settled with PTD - J&J were spewing at that 'apparently'. So the market hasn't valued the win against J&J - they also haven't valued the extremely high likelyhood of Thromboview coming to market - a fair swap? maybe , maybe not but those are the risks we are exchanging. Otherwise the 2 companies are a match made in heaven - manufacturing and IP rolled into 1. Plus the potential for production of generics now - they do own the IP so maybe its worth making the products and taking the bigger margin - who knows.
Did I mention they are very confident of winning the case against J&J?
read the note...., page-7
Add CT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $2.949M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $100 | 50.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 5505244 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 17370405 | 11 |
View Market Depth
| Last trade - 10.29am 21/06/2024 (20 minute delay) ? |
| CT1 (ASX) Chart |